Yilmaz, N.Emmungil, H.Gucenmez, S.Ozen, G.Yildiz, F.Balkarli, A.Kimyon, G.Coskun, B. N.Dogan, I.Pamuk, O. N.Yasar, S.Cetin, G. YildirimYazici, A.Esmen, S. ErguluCagatay, Y.Yilmaz, S.Celle, A.Cefle, A.Sayarhoglu, M.Kasifoglu, T.Karadag, O.Pehlivan, Y.Dalilic, E.Kisacik, B.Cobankara, V.Erken, E.Direskeneli, H.Aksu, K.Yavuz, S.2019-10-272019-10-2720150392-856X1593-098Xhttps://hdl.handle.net/11454/5203911th International Congress on Systemic Lupus Erythematosus -- SEP 02-06, 2015 -- Vienna, AUSTRIAeninfo:eu-repo/semantics/closedAccessMalignancy risk in systemic Lupus Erythematosus patients treated with cyclophosphamideConference Object333S67S67WOS:000360421900240Q2